MRTX849 in Patients With Cancer Having a KRAS G12C Mutation
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/26/2019 |
| Start Date: | January 15, 2019 |
| End Date: | April 2020 |
| Contact: | Mirati Therapeutics Study Locator Services |
| Email: | miratistudylocator@emergingmed.com |
| Phone: | 1-844-893-5530 |
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
Evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of
MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.
MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.
Evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and
clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C
mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.
clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C
mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.
Inclusion Criteria:
- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
- Unresectable or metastatic disease
- Standard treatment is not available or patient declines
- Adequate organ function
Exclusion Criteria:
- Active brain metastases
- History of intestinal disease or major gastric surgery or inability to swallow oral
medications
- Other active cancer
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials